|
Synonyms: IMO-2125 | IMO2125
Compound class:
Nucleic acid
Comment: Tilsotolimod (IMO-2125) is a phosphorothioate (P-thio) CpG oligonucleotide that is intended to act as a Toll-like receptor 9 (TLR9) agonist. Structurally it is a symmetrical, dual-strand 3'-3'-linked molecule.
Full sequence is : O,O'-(2-hydroxypropane-1,3-diyl) bis(hydrogen all-P-ambo-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-P-thio-3'-guanylate) |
| References |
|
1. Diab A, Ascierto PA, Maio M, Abdel-Wahab R, Negrier S, Mortier L, Arenberger P, Dalle S, Krajsova I, de la Cruz L et al.. (2025)
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). J Clin Oncol, 43 (15): 1800-1809. [PMID:40048691] |
|
2. Karapetyan L, Luke JJ, Davar D. (2020)
Toll-Like Receptor 9 Agonists in Cancer. Onco Targets Ther, 13: 10039-10060. [PMID:33116588] |
|
3. Wang D, Jiang W, Zhu F, Mao X, Agrawal S. (2018)
Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy. Int J Oncol, 53 (3): 1193-1203. [PMID:29956749] |